It is widely assumed that acute benefit of statin therapy is mediated especially by non-lipid effects. The immediate influence of statins on lipid levels in patients with acute coronary syndrome (ACS) is, however, not clear. A total of 64 consecutive patients with ACS were randomized at admission to fluvastatin 80 mg (Group 1, N = 32) or standard therapy without statin (Group 2, N = 32). The levels of total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), high-density-lipoprotein cholesterol (HDL-C), and triglycerides (TG) were examined at admission and after 24 h. Baseline characteristics were comparable in both groups. In Group 1, fluvastatin significantly decreased the levels of TC by 14.5%, LDL-C by 17.2%, and HDL-C by 10.0% (P < 0.001); TG were not influenced. In Group 2 only marginal reductions in TC (by 4.1%, P = 0.03) and HDL-C (by 7.5%, P < 0.01) were detected; the levels of LDL-C and TG were not changed. As compared with Group 2, in Group 1 the final levels of TC (P = 0.02) and LDL-C (P = 0.01) were significantly lower. Fluvastatin therapy, when started at admission in patients with ACS, significantly reduces TC and LDL-C already after 24 h. We suggest that the lipid-lowering effect of statins in the therapy of ACS is probably as prompt as non-lipid effects.

Department of Cardiology Charles University Prague 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Clin Cardiol. 2003 Oct;26(10):472-6 PubMed

Exp Clin Cardiol. 2005 Spring;10(1):9-16 PubMed

Int J Clin Pract. 2006 Jun;60(6):716-27 PubMed

JAMA. 2004 Sep 15;292(11):1307-16 PubMed

Heart Vessels. 2006 Sep;21(5):291-7 PubMed

N Engl J Med. 1996 Oct 3;335(14):1001-9 PubMed

J Am Coll Cardiol. 2003 Feb 5;41(3):508-15 PubMed

J Cardiovasc Pharmacol. 2000 Nov;36(5):617-21 PubMed

JAMA. 2006 May 3;295(17):2046-56 PubMed

Int J Cardiol. 2006 Apr 28;109(1):48-52 PubMed

Eur Heart J. 2002 Dec;23(24):1931-7 PubMed

Int J Cardiol. 2005 May 11;101(1):111-4 PubMed

Am J Cardiol. 2005 Sep 5;96(5A):54F-60F PubMed

N Engl J Med. 1998 Nov 5;339(19):1349-57 PubMed

Am Heart J. 2005 Mar;149(3):451-7 PubMed

J Cardiovasc Pharmacol. 2004 Sep;44(3):348-55 PubMed

Mol Cell Biochem. 2003 Apr;246(1-2):45-50 PubMed

Circulation. 2002 Feb 19;105(7):868-73 PubMed

N Engl J Med. 2004 Apr 8;350(15):1495-504 PubMed

Am Heart J. 2004 Jul;148(1):e2 PubMed

Med Hypotheses. 2005;64(1):192-6 PubMed

Am J Cardiol. 2000 Dec 15;86(12):1293-8 PubMed

Clin Chim Acta. 2006 Jun;368(1-2):168-72 PubMed

Lancet. 1994 Nov 19;344(8934):1383-9 PubMed

Circulation. 2001 Jul 24;104(4):376-9 PubMed

Arch Intern Med. 2006 Sep 25;166(17):1814-21 PubMed

Curr Control Trials Cardiovasc Med. 2005 Mar 24;6(1):4 PubMed

JAMA. 2001 Apr 4;285(13):1711-8 PubMed

Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers

Statins as first-line therapy for acute coronary syndrome?

Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome

Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)